Jill Hallin

Also affiliated with Bristol-Myers Squibb (Italy)

Biochemistry, Genetics and Molecular BiologyMedicinePharmacology, Toxicology and Pharmaceutics

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 10 papers. Top paper: “Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS G12D Inhibitor”.

Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS G12D Inhibitor

Journal of Medicinal Chemistry(2021)10.1021/acs.jmedchem.1c01688

N/A

0DataRank · unranked

716 citations

Shelley Allen, James F. Blake, Vickie Bowcut, David M. Briere, Andrew Calinisan +23 more

Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor

Nature Medicine(2022)10.1038/s41591-022-02007-7

N/A

0DataRank · unranked

519 citations

Vickie Bowcut, Andrew Calinisan, David M. Briere, Lauren Hargis, Lars D. Engstrom +25 more

A Non-covalent KRASG12D Allele Specific Inhibitor Demonstrates Potent Inhibition of KRAS-dependent Signaling and Regression of KRASG12D-mutant Tumors

Research Square(2022)10.21203/rs.3.rs-1261963/v1

N/A

0DataRank · unranked

1 citations

Jill Hallin, Vickie Bowcut, Andrew Calinisan, David M. Briere, Lauren Hargis +25 more

Alveolar Differentiation Drives Resistance to KRAS Inhibition in Lung Adenocarcinoma

Cancer Discovery(2023)10.1158/2159-8290.cd-23-0289

N/A

0DataRank · unranked

69 citations

Xueqian Zhuang, Chun‐Hao Pan, Yan Yan, Rohit Thummalapalli, Jill Hallin +12 more

Alveolar differentiation drives resistance to KRAS inhibition in lung adenocarcinoma

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.09.29.560194

N/A

0DataRank · unranked

2 citations

Xueqian Zhuang, Chun‐Hao Pan, Yan Yan, Rohit Thummalapalli, Jill Hallin +12 more

Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer

Cancer Discovery(2024)10.1158/2159-8290.cd-24-0177

N/A

0DataRank · unranked

243 citations

Megan T. Hoffman, Laleh Abbassi, Ziyue Li, Francesca Paradiso, Brendan D. Parent +50 more

The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading

Molecular Cancer Therapeutics(2024)10.1158/1535-7163.mct-23-0870

N/A

0DataRank · unranked

33 citations

Larry Yan, Fadia Qiryaqos, Lars D. Engstrom, Jade Laguer, Andrew Calinisan +29 more

Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-2310

N/A

0DataRank · unranked

21 citations

Alvaro G. Paula, David Molkentine, Laura D. Hover, Monique B. Nilsson, Natalie I. Vokes +17 more

Combination therapy of adagrasib and abemaciclib in non-small cell lung cancer brain metastasis models genomically characterized by KRAS-G12C and homozygous loss of CDKN2A

Acta Neuropathologica Communications(2025)10.1186/s40478-025-01993-2

N/A

0DataRank · unranked

5 citations

Yinon Sadeh, Consuelo Torrini, Fatma Turna Demir, Naema Nayyar, Erika Yamazawa +10 more

Molecular MRI of Dysregulated Zinc Secretion Detects Pancreatic Ductal Adenocarcinoma and Response to KRAS G12D Inhibitor Treatment

Cancer Research(2025)10.1158/0008-5472.can-24-3384

N/A

0DataRank · unranked

1 citations

Mozhdeh Sojoodi, Farzad Moloudi, Patricia Gonzalez Pagan, Manyu Jin, Pamela Pantazopoulos +15 more